They came. We saw. They disrupted.
On Friday, I recapped our latest biotech event, “Boston’s Life Science Disruptors,” with some key takeaways from the stars of the show: Genocea Biosciences, Moderna Therapeutics, and Bluebird Bio (NASDAQ: [[ticker:BLUE]]). Today, as promised, I’ve circled back with a slideshow look at the festivities, including shots of the speakers, and you, our audience.
Again, big thanks to KeithSpiroPhoto courtesy of Kendall PRess for the pictures. Great thanks as well to our speakers, our event host, Novartis Institutes for Biomedical Research–and to our sponsors: BDO, Cubist, Health Advances, the Kauffman Foundation, and Mintz Levin.
Author: Ben Fidler
Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
View all posts by Ben Fidler
